These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38440933)

  • 1. PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer.
    Dhull A; Wei J; Pulukuri AJ; Rani A; Sharma R; Mesbahi N; Yoon H; Savoy EA; Xaivong Vi S; Goody KJ; Berkman CE; Wu BJ; Sharma A
    Nanoscale; 2024 Mar; 16(11):5634-5652. PubMed ID: 38440933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA-Targeted 2-Deoxyglucose-Based Dendrimer Nanomedicine for the Treatment of Prostate Cancer.
    Rani A; Pulukuri AJ; Wei J; Dhull A; Dar AI; Sharma R; Mesbahi N; Savoy EA; Yoon H; Wu BJ; Berkman CE; Sharma A
    Biomacromolecules; 2024 Sep; 25(9):6164-6180. PubMed ID: 39164913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation.
    Lesniak WG; Boinapally S; Lofland G; Jiang Z; Foss CA; Behman Azad B; Jablonska A; Garcia MA; Brzezinski M; Pomper MG
    Int J Nanomedicine; 2024; 19():4995-5010. PubMed ID: 38832336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
    Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
    Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
    Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modular Smart Molecules for PSMA-Targeted Chemotherapy.
    Olatunji FP; Pun M; Herman JW; Romero O; Maniatopoulos M; Latoche JD; Parise RA; Guo J; Beumer JH; Anderson CJ; Berkman CE
    Mol Cancer Ther; 2022 Nov; 21(11):1701-1709. PubMed ID: 35999662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
    Kularatne SA; Wang K; Santhapuram HK; Low PS
    Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Choy CJ; Ling X; Geruntho JJ; Beyer SK; Latoche JD; Langton-Webster B; Anderson CJ; Berkman CE
    Theranostics; 2017; 7(7):1928-1939. PubMed ID: 28638478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of PSMA-specific peptide ligands for targeted drug delivery.
    Jin W; Qin B; Chen Z; Liu H; Barve A; Cheng K
    Int J Pharm; 2016 Nov; 513(1-2):138-147. PubMed ID: 27582001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
    Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
    Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a PSMA-targeted BNF nanoparticle construct.
    Behnam Azad B; Banerjee SR; Pullambhatla M; Lacerda S; Foss CA; Wang Y; Ivkov R; Pomper MG
    Nanoscale; 2015 Mar; 7(10):4432-42. PubMed ID: 25675333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
    Wang S; Blaha C; Santos R; Huynh T; Hayes TR; Beckford-Vera DR; Blecha JE; Hong AS; Fogarty M; Hope TA; Raleigh DR; Wilson DM; Evans MJ; VanBrocklin HF; Ozawa T; Flavell RR
    Mol Pharm; 2019 Sep; 16(9):3831-3841. PubMed ID: 31381351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
    Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
    J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
    Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
    Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSMA-targeted dendrimers: a patent evaluation (WO2012078534).
    Akhtar NH; Osborne JR; Fareedy SB; Tagawa ST
    Expert Opin Ther Pat; 2013 May; 23(5):665-8. PubMed ID: 23581819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
    Saniee F; Shabani Ravari N; Goodarzi N; Amini M; Atyabi F; Saeedian Moghadam E; Dinarvand R
    Pharm Dev Technol; 2021 Apr; 26(4):381-389. PubMed ID: 33538232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
    Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
    Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.